stockrow
Friday 6 November 2026
Export PODD’s income statement to Excel — free account
Insulet Corporation
PODD Healthcare Medical Devices
Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024.
- Revenue
- +19.2%
- EPS
- +64.1%
- Free cash flow
- −29.8%
- Total debt
- −5.19%
Quarter to September 2026, against a year earlier
146.38
9.74
−6.24%
Follow PODD
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 1,322.00 | 951.11 | 2,323.91 | 1,156.83 | 4,091.14 | 70.88 | 43.66 | 81.21 |
Piotroski F-Score |
6 | 5 | 6 | 5 | 5 | 4 | 4 | 6 | 8 | 6 |
P/S ratio |
5.83 | 8.63 | 8.28 | 14.05 | 18.30 | 16.39 | 15.22 | 8.59 | 8.83 | 7.38 |
Altman Z-Score |
2.76 | 3.64 | 4.03 | 6.26 | 8.56 | 8.18 | 7.68 | 6.15 | 7.40 | 9.09 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 399.61 | 61.76 | 57.15 |
Altman Z″-Score (non-manufacturers) |
(0.33) | 0.99 | 0.55 | 0.94 | 3.17 | 3.30 | 2.31 | 3.38 | 4.29 | 4.78 |
Beneish M-Score |
(3.23) | (1.56) | (2.17) | (3.07) | (2.49) | (1.72) | (2.18) | (1.85) | (2.35) | (2.59) |
P/Operating CF |
106.54 | 182.81 | 153.38 | 221.19 | 973.42 | (706.37) | 391.87 | 322.69 | 124.03 | 109.09 |
P/B ratio |
33.86 | 25.25 | 22.01 | 136.68 | 27.42 | 32.38 | 41.70 | 19.91 | 15.10 | 13.20 |
Price to Tangible BV |
99.77 | 35.01 | 28.80 | 453.00 | 30.93 | 37.53 | 56.89 | 25.05 | 17.23 | 14.85 |
EV/Sales |
5.98 | 8.95 | 8.86 | 14.75 | 18.42 | 16.83 | 15.78 | 9.01 | 9.04 | 7.47 |
EV/EBITDA |
701.95 | 638.80 | 116.18 | 139.79 | 155.85 | 100.84 | 204.31 | 52.23 | 48.04 | 35.85 |
EV/Operating CF |
138.04 | 100.54 | 139.16 | 110.67 | 198.33 | (271.58) | 173.06 | 104.99 | 43.52 | 35.53 |
EV/FCF |
(354.03) | (127.76) | (38.46) | (150.20) | (201.94) | (96.93) | (537.72) | 419.10 | 63.20 | 57.81 |
Quick Ratio |
5.88 | 5.74 | 3.16 | 2.82 | 5.02 | 4.16 | 2.41 | 2.36 | 2.50 | 1.81 |
Current Ratio |
6.64 | 6.24 | 3.99 | 3.75 | 6.01 | 5.81 | 3.60 | 3.51 | 3.58 | 2.81 |
Net Debt/EBITDA |
10.93 | 19.40 | 7.05 | 6.62 | 1.04 | 2.63 | 7.21 | 2.43 | 1.09 | 0.41 |
Debt/Assets |
72.87% | 69.32% | 63.75% | 78.04% | 56.56% | 62.18% | 62.27% | 54.70% | 44.69% | 29.75% |
Debt/Equity |
5.27 | 3.57 | 2.79 | 11.75 | 1.76 | 2.29 | 2.94 | 1.93 | 1.14 | 0.63 |
Asset Turnover |
1.00 | 0.73 | 0.65 | 0.71 | 0.60 | 0.56 | 0.61 | 0.70 | 0.73 | 0.86 |
Operating CF/Net income |
(0.55) | (1.54) | 10.88 | 8.48 | 12.35 | (4.05) | 25.87 | 0.71 | 1.03 | 2.30 |
Capex/Depreciation |
(1.60) | (5.55) | (10.41) | (6.13) | (3.01) | (2.14) | (2.49) | (1.50) | (1.66) | (2.43) |
Interest Coverage |
(0.74) | (0.35) | 1.29 | 1.81 | 1.14 | 2.04 | 1.04 | 6.08 | 7.23 | 7.98 |
| (59.42%) | (24.18%) | 1.78% | 8.06% | 2.00% | 2.90% | 0.89% | 34.12% | 43.03% | 18.12% | |
| (7.89%) | (4.21%) | 0.38% | 1.12% | 0.45% | 0.86% | 0.21% | 8.53% | 14.74% | 7.87% | |
ROIC |
(6.87%) | (1.62%) | 3.32% | 5.28% | 4.50% | 7.58% | 1.95% | 9.52% | 11.79% | 16.94% |
Return on Tangible Assets |
(8.04%) | (4.79%) | 0.55% | 1.39% | 0.45% | 1.03% | 0.30% | 11.48% | 20.05% | 12.03% |
Average Days of Receivables |
28.65 | 42.00 | 49.66 | 34.27 | 38.46 | 53.48 | 57.49 | 77.36 | 64.40 | 69.67 |
Research and Development Expense of Revenue |
15.18% | 16.32% | 15.79% | 17.92% | 16.23% | 14.57% | 13.81% | 12.08% | 10.60% | 11.12% |
Selling, General and Administrative Expense of Revenue |
45.25% | 45.04% | 43.99% | 40.37% | 42.46% | 42.41% | 45.03% | 43.30% | 44.27% | 43.02% |
Intangible Assets out of Total Assets |
0.09 | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 | 0.06 | 0.06 | 0.05 | 0.05 |
Share Based Compensation of Revenue |
6.44% | 6.88% | 6.65% | 3.89% | 3.97% | 3.13% | 3.13% | 2.85% | 3.35% | 2.32% |
Graham Net Nets |
(0.01) | (0.03) | (0.05) | (0.05) | 0.00 | (0.01) | (0.02) | (0.02) | 0.00 | 0.01 |
Graham Number |
0.00 | 0.00 | 2.21 | 2.25 | 4.80 | 6.52 | 3.29 | 26.41 | 48.23 | 41.19 |
Earnings Yield |
(1.37%) | (0.67%) | 0.08% | 0.11% | 0.04% | 0.09% | 0.02% | 1.41% | 2.29% | 1.23% |
Free Cash Flow Yield |
(0.29%) | (0.81%) | (2.78%) | (0.70%) | (0.50%) | (1.06%) | (0.19%) | 0.25% | 1.62% | 1.75% |
Revenue per Share |
6.41 | 8.00 | 9.58 | 12.18 | 13.97 | 16.23 | 18.82 | 24.33 | 29.56 | 38.50 |
Operating CF per Share |
0.28 | 0.71 | 0.61 | 1.62 | 1.30 | (1.01) | 1.72 | 2.09 | 6.14 | 8.09 |
Capex per Share |
(0.39) | (1.33) | (2.76) | (2.82) | (2.57) | (1.81) | (2.27) | (1.57) | (1.91) | (3.12) |
Free Cash Flow per Share |
(0.11) | (0.62) | (2.15) | (1.20) | (1.27) | (2.82) | (0.55) | 0.52 | 4.23 | 4.97 |
Cash per Share |
5.22 | 7.59 | 4.91 | 6.21 | 14.64 | 11.69 | 9.73 | 10.10 | 13.61 | 10.18 |
Shareholders Equity per Share |
1.10 | 2.73 | 3.60 | 1.25 | 9.32 | 8.22 | 6.87 | 10.50 | 17.29 | 21.54 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.10 | 2.73 | 3.60 | 1.25 | 9.32 | 8.22 | 6.87 | 10.50 | 17.29 | 21.54 |
Free Cash Flow |
(6.20) | (35.90) | (126.50) | (72.50) | (82.50) | (190.80) | (38.30) | 36.50 | 296.20 | 349.90 |
Working Capital |
314.26 | 451.15 | 345.60 | 433.30 | 1,040.90 | 1,101.00 | 949.30 | 1,131.70 | 1,362.90 | 1,233.90 |
Capital Expenditures |
(22.11) | (77.20) | (162.40) | (170.90) | (166.50) | (122.70) | (157.30) | (109.20) | (134.00) | (219.40) |
Net Current Asset Value |
(23.54) | (121.06) | (255.30) | (476.00) | (20.60) | (162.70) | (460.70) | (272.60) | 15.20 | 238.80 |
EV/EBIT |
0.00 | 0.00 | 187.68 | 217.79 | 323.49 | 146.78 | 547.73 | 69.50 | 60.61 | 42.69 |
Capex to Sales |
0.06 | 0.17 | 0.29 | 0.23 | 0.18 | 0.11 | 0.12 | 0.06 | 0.06 | 0.08 |
Price to Operating Income |
0.00 | 0.00 | 175.39 | 207.47 | 321.32 | 142.96 | 528.39 | 66.27 | 59.23 | 42.20 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.31 | 0.13 | 0.06 | 0.07 | 0.12 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 |
Cash ROIC |
(0.89%) | (3.08%) | (11.57%) | (5.39%) | (3.16%) | (7.28%) | (1.50%) | 1.28% | 8.36% | 11.00% |
Accounts Receivable Turnover |
10.29 | 11.29 | 8.67 | 10.11 | 10.99 | 8.57 | 7.12 | 6.00 | 5.71 | 6.14 |
Accounts Payable Turnover |
10.99 | 9.93 | 7.76 | 6.45 | 5.93 | 7.55 | 14.59 | 21.49 | 32.10 | 16.21 |
Inventory Turnover |
6.56 | 5.38 | 3.68 | 2.99 | 2.52 | 1.52 | 1.54 | 1.43 | 1.50 | 1.74 |
Average Days of Payables |
30.81 | 47.75 | 48.08 | 77.13 | 61.31 | 39.69 | 22.50 | 13.05 | 11.55 | 35.64 |
Days of Inventory on Hand |
83.15 | 66.10 | 134.61 | 142.94 | 174.85 | 319.20 | 253.32 | 273.55 | 250.99 | 215.05 |
Average Receivables |
35.67 | 41.09 | 65.04 | 73.00 | 82.30 | 128.15 | 183.30 | 282.65 | 362.60 | 441.20 |
Average Payables |
14.19 | 18.79 | 24.96 | 40.00 | 54.30 | 45.90 | 34.25 | 25.00 | 19.50 | 47.40 |
Average Inventory |
23.77 | 34.65 | 52.60 | 86.20 | 127.65 | 228.75 | 325.00 | 374.70 | 416.50 | 441.50 |
Average Assets |
365.89 | 636.70 | 872.72 | 1,035.80 | 1,507.90 | 1,960.85 | 2,149.95 | 2,419.65 | 2,837.95 | 3,139.05 |
Average Common Equity |
48.60 | 110.83 | 185.31 | 144.00 | 339.75 | 579.95 | 516.35 | 604.55 | 972.15 | 1,363.45 |
Columns are period end dates · fundamentals updated 5 Nov 2026